Enliven Therapeutics (ELVN) Interest & Investment Income (2019 - 2026)

Enliven Therapeutics has disclosed Interest & Investment Income across 8 years of filings, most recently posting $4.2 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $4.2 million, up 31.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.0 million (up 14.67% YoY), and the FY2025 annual result was $16.0 million, up 7.53% from the prior year.
• Interest & Investment Income came in at $4.2 million for Q1 2026 at Enliven Therapeutics, down from $4.6 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $4.9 million in Q3 2025 to a low of $9000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $3.4 million (2023), against an average of $2.8 million.
• Across the five-year window, Interest & Investment Income slumped 89.16% in 2022 and soared 18722.22% in 2023, its largest moves.
• Enliven Therapeutics' Interest & Investment Income stood at $613000.0 in 2022, then surged by 449.43% to $3.4 million in 2023, then gained by 10.33% to $3.7 million in 2024, then grew by 24.27% to $4.6 million in 2025, then slipped by 9.14% to $4.2 million in 2026.
• The last three Interest & Investment Income figures came in at $4.2 million (Q1 2026), $4.6 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.